GLTO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases...

Stats
Today's Volume	26 148.00
Average Volume	225 788
Market Cap	18.14M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.410 ) 2024-04-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0.0120 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Schambye Hans T.	Buy	200 000	Restricted Stock Units
2024-01-03	Winslow Garrett	Buy	100 000	Restricted Stock Units
2024-01-03	Freve Jonathan	Buy	100 000	Restricted Stock Units
2023-08-15	Orbimed Advisors Llc	Sell	535 534	Common Stock
2023-08-15	Orbimed Advisors Llc	Sell	248 819	Common Stock

INSIDER POWER
-13.05
Last 96 transactions
Buy: 4 275 597 \| Sell: 1 504 628

Volume Correlation

Long: -0.04 (neutral)

Short: -0.13 (neutral)

Signal:(49.123) Neutral

Galecto, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Galecto, Inc. Correlation - Currency/Commodity

0.26
( neutral )

0.38
( neutral )

0.00
( neutral )

-0.06
( neutral )

Galecto, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-830 000 (0.00 %)
EPS:	$-1.440

Q4	2023
Revenue:	$1.20M
Gross Profit:	$973 000 (80.95 %)
EPS:	$-0.240

Q3	2023
Revenue:	$0
Gross Profit:	$-367 000 (0.00 %)
EPS:	$-0.300

Q2	2023
Revenue:	$0
Gross Profit:	$-95 000.00 (0.00 %)
EPS:	$-0.410

Financial Reports:

No articles found.

Galecto, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Realtime updates for Galecto, Inc. [GLTO]

Upcoming Earnings Alert